S1 Table. Comparison of clinical and treatment characteristics in patients with and without increased post-RT necrosis

	Post-RT necrosis		
	No or decreased	Increased	p-value
Age (yr)			
< 10	42 (45.2)	51 (54.8)	0.013
≥ 10	37 (66.1)	19 (33.9)	
Extrapontine extension			
No	15 (45.5)	18 (54.5)	0.301
Yes	64 (55.7)	51 (44.3)	
Tumor enhancement			
No	33 (62.3)	20 (37.7)	0.062
Yes	43 (46.2)	50 (53.8)	
Tumor margin			
Well-defined	28 (45.9)	33 (54.1)	0.127
Infiltrative	51 (58.6)	36 (41.4)	
Cyst or necrosis			
No	61 (63.5)	35 (36.5)	0.001
Yes	18 (34.0)	35 (66.0)	
RT modality			
2D	5 (71.4)	2 (28.6)	0.557
3D-CRT	32 (57.1)	24 (42.9)	
IMRT	32 (50.0)	32 (50.0)	
Proton	10 (45.5)	12 (54.5)	
RT dose			
< 54 Gy	20 (55.6)	16 (44.4)	0.726
≥ 54 Gy	59 (52.2)	54 (47.8)	
CCRT			
No	39 (53.4)	34 (46.6)	0.923
Yes	40 (52.6)	36 (47.4)	
Adj. chemotherapy			
No	51 (61.4)	32 (38.6)	0.021
Yes	28 (42.4)	38 (57.6)	

Values are presented as number (%).2D, 2-dimensional; 3D-CRT, 3-dimensional conformal radiotherapy; Adj., adjuvant; CCRT, concurrent chemoradiotherapy; IMRT, intensity-modulated radiotherapy; RT, radiotherapy.